UK Markets closed

Iovance Biotherapeutics, Inc. (0JDK.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
22.78-0.72 (-3.06%)
At close: 4:09PM BST
Currency in USD

Valuation measures

Market cap (intra-day) 53.07B
Enterprise value 33.87B
Trailing P/E N/A
Forward P/E 1N/A
PEG ratio (5-yr expected) 1N/A
Price/sales (ttm)N/A
Price/book (mrq)5.10
Enterprise value/revenue 3N/A
Enterprise value/EBITDA 7-14.85

Trading information

Stock price history

Beta (5Y monthly) 0.82
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 322.79
52-week low 322.78
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 5123.17M
Implied shares outstanding 6N/A
Float 130.38M
% held by insiders 10.62%
% held by institutions 1104.45%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2020
Most-recent quarter (mrq)31 Dec 2020

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-29.41%
Return on equity (ttm)-54.34%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -260.8M
Net income avi to common (ttm)-259.58M
Diluted EPS (ttm)-1.88
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)629.44M
Total cash per share (mrq)4.28
Total debt (mrq)51.66M
Total debt/equity (mrq)7.87
Current ratio (mrq)11.59
Book value per share (mrq)4.47

Cash flow statement

Operating cash flow (ttm)-205.13M
Levered free cash flow (ttm)-148.97M